Abstract: Emollient compositions and their use to treat inflammatory skin disorders including plaque psoriasis, particularly emollient compositions comprising a combination of linoleic acid and conjugated linoleic acid.

Abstract: An applicator used for spreading compositions such as ointments, creams, lotions, or foams to a subject's skin or other external part of the body. The applicator includes a handle, an extendable and retractable telescopic shaft and a rectangular, diamond shaped head. In one embodiment, the rectangular, diamond shaped head includes a center ridge which serves to define three separate flexible wedge like surfaces on each side of the head.

Abstract: Methods of making metaxalone tablets having consistent dissolution properties and bioavailability, and tablets manufactured thereby.

Abstract: A method of neuroinflammation and conditions associated therewith including chronic and acute conditions as well as specific and non-specific conditions. Oral dosage forms containing 640 mg micronized and non-micronized particulate metaxalone and excipients including alginic acid and propylene glycol alginate. The method includes inhibiting the monoamine oxidase A (MAO-A) enzyme as well as restoring/upregulating/increasing IL-13 and PGC-1?. The treated conditions, among others, include diabetic neuropathy, fibromyalgia, back pain, chronic pain induced depression, restless leg syndrome, anxiety, mood disorder, peripheral neuropathy, and herpetic neuralgia. The method further includes inducing or restoring homeostasis, restoring oxidative homeostasis, restoring basal phenotype from a neuroinflammatory state and improving neuroplasticity.

Abstract: The present invention relates to a series of substituted dihydro and tetrahydro oxazolopyrimidinones, specifically, to a series of 2-substituted-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-ones and 2-substituted-2,3,5,6-tetra-hydro-oxazolo[3,2-a]pyrimidin-7-ones of formula (I): Wherein p, n, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of this invention are modulators of metabotropic glutamate receptors (mGluR), particularly, mGluR2 receptor. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic neurodegenerative conditions, psychoses, convulsions, anxiety, depression, migraine, pain, sleep disorders and emesis.

Abstract: The present invention relates to a series of substituted dihydro and tetrahydro oxazolopyrimidinones, specifically, to a series of 2-substituted-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-ones and 2-substituted-2,3,5,6-tetra-hydro-oxazolo[3,2-a]pyrimidin-7-ones of formula (I): Wherein p, n, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of this invention are modulators of metabotropic glutamate receptors (mGluR), particularly, mGluR2 receptor. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic neurodegenerative conditions, psychoses, convulsions, anxiety, depression, migraine, pain, sleep disorders and emesis.